The intratumoral administration of talimogene laherparepvec (T-VEC) as an oncolytic virus combined with anti-PD-1 boosted antitumor response in patients with unresectable stage III–IV metastatic melanoma [164,165]. Here, PDCD1 is linked to metastatic melanoma.